



MARKET RELEASE

11 March 2016

Clinuvel Pharmaceuticals Ltd

TRADING HALT

The securities of Clinuvel Pharmaceuticals Ltd (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 15 March 2016 or when the announcement is released to the market.

Security Code: CUV

James Gerraty

MANAGER, LISTINGS COMPLIANCE (MELBOURNE)

For personal use only



Mr James Gerraty
Manager Listings, Melbourne
Level 45, Rialto South Tower
525 Collins Street, Melbourne
VIC
3000

By email: James.Gerraty@asx.com.au, tradinghaltmelbourne@asx.com.au

March 11, 2016

Re: REQUEST FOR TRADING HALT

Dear Mr Gerraty,

Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV) requests a trading halt with respect to its ordinary shares from the commencement of trading on Friday 11th March 2016 until the commencement of trading Tuesday 15th March, 2016.

The trading halt is necessary as CUV proposes to make an announcement to the market regarding a proposed capital raising.

The trading halt is to last until the earlier of CUV releasing an announcement, or until the commencement of trade on Tuesday 15th March, 2016.

CUV is not aware of any reason why the trading halt should not be granted by the ASX nor is it aware of any other information that is necessary to inform the market about the trading halt.

Yours faithfully,

Darren Keamy
Company Secretary
Clinuvel Pharmaceuticals Ltd

Australian Office: Level 14, 190 Queen Street Melbourne Victoria 3000 Australia T +61 3 9660 4900

European Office: Neuhofstrasse 3D, 6340 Baar, Switzerland T +41 41 767 4545

US Office: 40 Worth Street, Suite 1053, Floor 10 New York, NY 10013, USA T +1 646 527 7310

Singapore Office: 9 Temasek Boulevard, #29-01, Singapore 038989 T +65 315 751 34

www.clinuvel.com